![]() Please see full Prescribing Information and Patient Information for NUCALA. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses therefore, potential effects on a fetus are likely to be greater during the second and third trimesters. To enroll call 1-87 or visit The data on pregnancy exposures are insufficient to inform on drug-associated risk. Manifestations included rash, pruritus, headache, myalgia, and flushing the majority were experienced the day of dosing.Ī pregnancy exposure registry monitors pregnancy outcomes in women exposed to NUCALA during pregnancy. Systemic reactions (allergic and nonallergic), including hypersensitivity, also occurred. Eosinophilia occurs when a large number of eosinophils are recruited to a specific site in your body or when the bone marrow produces too many eosinophils. In clinical trials in patients receiving NUCALA, the most common adverse reactions (≥5%) were headache, injection site reaction, back pain, and fatigue. Function : These cells are born in the bone marrow, and. Pearson correlation analysis showed that a low percentage blood eosinophil level was negatively associated with higher WBC count (r0.155, P<0.05). ![]() If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves. Eosinophils are fairly rarely found in blood smears - making up 1-6 of the total white blood cells. Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Consider vaccination if medically appropriate.ĭo not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. In controlled clinical trials, 2 serious adverse reactions of herpes zoster occurred with NUCALA compared to none with placebo. Eosinophils usually make up between 0-6 of the white blood cells. NUCALA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm. If a hypersensitivity reaction occurs, discontinue NUCALA.Īcute Asthma Symptoms or Deteriorating Disease These reactions generally occur within hours of administration but can have a delayed onset (ie, days). Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.
0 Comments
Leave a Reply. |